2-Aminophenoxazine-3-one Suppresses the Growth of Mouse Malignant Melanoma B16 Cells Transplanted into C57BL/6Cr Slc Mice
bation, the number of viable cells was counted by microscopy. A WST-1 Cell Counting Kit (Dojin East, Tokyo, Japan) was used to assess cell proliferation, and absorption was measured at 450 nm. The viability of cells was determined by the trypan blue dye exclusion test.
Animal Female C57BL/6Cr Slc mice were obtained at 6 weeks of age from Japan SLC (Hamamatsu, Japan). The mice were maintained in the Laboratory for Animal Experiments, Chiba Institute of Technology, with free access to Charles River solid rodent chow (Oriental Yeast, Tokyo) and water under filtered laminar air-flow conditions at 21Ϯ1°C, 60Ϯ5% humidity and 12 h light a day. They were acclimatized for 7 d before the experiments.
Cancer cell line and transplantation 10 6 cells of mouse malignant melanoma B16 cells were inoculated s.c. into the flank of C57BL/6Cr Slc mice in a volume of 0.1 ml, on day 0 and then Phx-3 (0.5 mg/kg) was daily given i.p. for 12 consecutive days starting with the day of transplantation. The size of the subcutaneous tumor was measured with Vernier calipers in terms of two dimensions at right angles and expressed as volume (mm 3 ) calculated as follows: 4/3ϫpϫ(long diameter/2)ϫ(short diameter/2) 2 .
Laboratory Examinations
The animals were sacrificed by decapitation, 12 d after the transplantation of malignant melanoma B16 cells with or without Phx-3, and were subjected to pathological examination and assessment of serum levels of the blood biochemical parameters including aspartate aminotransferase (AST, or GOT), alanine aminotransferase (ALT, or GPT), blood urea nitrogen (BUN) and creatinine.
Pathological Examination Morphology of the liver, kidney and skin in the control mice and the mice transplanted with mouse malignant melanoma B16 cells and treated with 0.5 mg/kg Phx-3 was examined microscopically, after preserving the tissues in 10% formalin, treating them with paraffin, sectioning at nominal thickness of 5 mm, and staining them with hematoxylin eodin (HE) for the liver and kidney and with silver ammonium for the skin (Fontana-Masson method).
14)
Analysis of Serum Levels of Blood Biochemical Parameters Blood chemistry including the measurement of AST, ALT, blood urea nitrogen (BUN) and creatinine was examined by a Fuji Drychem 3500 automated analyzer (Fuji Medical System Co. Ltd., Tokyo).
Statistics The results were expressed as mean valuesϮS.E.M. The data for tumor size were ranked and subjected to the Kruskal-Wallis test, and then non-parametric Duncan's multiple range test (ranked multiple range test) to analyze the significance of differences between the control and the compound-treated groups. For the other data including body weight, we used the parametric Duncan's multiple range test after one-way analysis of variance (ANOVA) was used to assess the statistical significance of differences between the control and the compound-treated groups. A value of pՆ0.05 was considered to indicate a significant difference in all statistical analyses.
RESULTS

Effects of Phx-3 on Tumor Proliferation in Vitro
We studied the inhibitory effects of Phx-3 on the proliferation of mouse malignant melanoma B16 cells in vitro. As shown in Fig. 2 , Phx-3 inhibited the proliferation of mouse malignant melanoma B16 cells dependent on time and dose. The proliferation of the cells was inhibited by about 80% at 48 h, and almost completely (more than 90%) at 72 h, in the presence of 41.3 mM Phx-3. The present results demonstrate that Phx-3 may exert anticancer effects on mouse malignant melanoma B16 cells in vitro.
Effects of Phx-3 on Tumor Proliferation in Vivo Since Phx-3 showed anti-proliferative effects of mouse malignant melanoma B16 cells in vitro, we further examined the anticancer effects of Phx-3 on the cells transplanted into C57BL/6Cr Slc mice. The photos in Fig. 3 show the cutaneous (the upper column) and subcutaneous (lower column) appearances of the tumor after the transplantation of melanoma cells into the flank of mice with or without Phx-3. No tumor formation was observed in the mice receiving 0.5 mg/kg Phx-3, while tumor formation was extensive in the mice without Phx-3.
The changes in tumor size of mouse malignant melanoma B16 cells in the mice are shown in Fig. 4 . It was found that Phx-3 at 0.5 mg/kg caused no increase of tumor in the flanks of mice. The skin specimens were obtained from several sites where mouse malignant melanoma B16 cells were inoculated. The figures show the representative tissues of these specimens. group during the experiment. As shown in Fig. 6 , no significant pathlogical changes were observed in the liver (Fig. 6A ) and the kidney (Fig. 6B ) of mice treated with Phx-3 (0.5 mg/kg) after subcutaneous injection of malignant melanoma B16 cells into the flank. Blood chemistry revealed that there were no significant differences in AST, ALT, BUN and creatinine in the serum of the control mice and the mice treated with Phx-3 (0.5 mg/kg) after subcutaneous injection of malignant melanoma B16 cells into the flank (Table 1) . Figure 7 shows the microscopic analysis of the Fontana Mason-stained skin tissue from a positive control mouse with melanoma (Figs. 7A, B) , and from a mouse treated with Phx-3 after transplantation of melanoma cells (Fig. 7C) . As is seen in Figs. 7A and B, the tumor cell contained a fine dusting of melanin pigment within the cytoplasm in a positive control. On the contrary, a tumor was not formed in this tissue at all and the inoculated melanoma cells disappeared completely in the mouse treated with Phx-3 after transplantation of melanoma cells (Fig. 7C) . These results are consistent with our finding shown in Figs. 3 and 4.
DISCUSSION
We examined the inhibitory effects of Phx-3, which was produced by the reaction of o-aminophenol with bovine hemoglobin, 13) on the growth of mouse malignant melanoma B16 cells in vitro and in vivo. In vitro, the proliferation of the cells was inhibited by Phx-3, dose and time dependently, and was almost completely inhibited by 41.5 mM Phx-3 (Fig. 2) . This result is comparable to our previous report on the anticancer activity of Phx-3 against human malignant melanoma G361 cells 11) and on that of Phx-1 against various cancer cell lines. [6] [7] [8] [9] [10] We furthermore demonstrated that the growth of mouse malignant melanoma B16 cells transplanted into C57BL/6Cr Slc mice was completely inhibited by the administration of 0.5 mg/kg Phx-3 (Figs. 3, 4) . This result was confirmed by the pathological examination shown in Figs. 7A-C. These results suggest that Phx-3 exerts the strong anticancer activity against mouse malignant melanoma B16 cells. In the light of the empirical findings that chemotherapeutic agents including 5-fluorouracil (5-FU) exert the anticancer activity at less than 1 mM in vitro, and several mg/kg in vivo, 8) our present results in Figs. 2 and 5 revealed that Phx-3 exerts its anticancer activity against mouse melanoma B16 cells at extremely low concentrations (0.5 mg/kg Phx-3), in the mouse transplanted with B16 cells, compared with the case of B16 cells in vitro (41.5 mM Phx-3). Similar results have been also obtained for Phx-1 administered to mice transplanted with Meth A carcinoma cells 8) or human leukemia cells. 9) A plausible explanation for the difference in anticancer activity in vitro and in vivo may be that Phx-3 was metabolized to more effective metabolites in mice and that Phx-3 might act synergistically with various cytokines in the body. For example, Hara et al. 15) found that the anticancer effects of Phx-1 were enhanced as much as hundred times, when Jurkat cells, a human T leukemic cell line, were treated with Phx-1 in combination with TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). These views are currently speculative, and should await further investigation.
It has been shown that many anticancer drugs exert adverse effects including the decrease of body weight, piloerection, and dysfunction of the inner organs. As shown in Fig. 5 , no significant weight loss was indicated (Fig. 5) . In addition, no pathological changes were observed in the liver and the kidney of mice treated with Phx-3 (0.5 mg/kg) after subcutaneous injection of malignant melanoma B16 cells into the flank (Figs. 6A, B) , and there were no significant differences in AST, ALT, BUN and creatinine in the serum of the melanoma-transplanted mice with Phx-3 ( Table 1 ). These results suggest that Phx-3 causes few adverse effects on mice. When 5 mg/kg 5-FU was administered to mice, these adverse effects were significantly observed in mice, causing the death. 8) Actinomycin D is shown to have anticancer effects, however exerts strong adverse effects. 12) Though the phenoxazine is an essential component of Actinomycin D, Eckert and Eyer 16) demonstrated that Phx-3 and several phenoxazines are not toxic to dogs. Our present results are in good agreement with those of Eckert and Eyer. 16) With regard to Phx-1, it caused strong anticancer effects against human leukemia cell line HAL-01 and Meth A cancer cells transplanted into BALB/c mice with limited adverse effects. 8, 9) The few adverse effects of Phx-3 and Phx-1 may be attributed to the fact that the chemical structure of these phenoxazines ( Fig. 1 ) is analogous to that of vitamin B 2 , composed of the phenazine ring (isoalloxazine). The mechanism for few adverse effects of Phx-1 and Phx-3 should await further investigation, though the various biological effects of Phx-1 and Phx-3 including antitumor activities, immunosuppressive effects and antiviral effects etc. [17] [18] [19] [20] have been recently reported.
Malignant melanoma is now one of the most common malignancy in the world, and a highly lethal disease. 1, 2) Only dacarbazine is currently approved for the treatment among many chemotherapeutic agents, however, its objective response rate is 10-15%. 3, 21) This agent is included for most combination regimens. Since we showed the anticancer effect of Phx-3 on mouse malignant melanoma B16 cells in vitro and in vivo, in the present study, and Phx-3 seems to have few adverse effects on mice, it may be possible to apply Phx-3 to the treatment of patients with malignant melanoma, in combination with dacarbazone or as a single dose, in future. Phx-3 may be expected to be useful as an anticancer agent against human malignant melanoma, which is extremely resistant to chemotherapy. 1, 2, 21) 
